Velcera Receives FDA Feedback on Innovative Canine Allergy Product (Marketwire via Yahoo! Finance)
Velcera, Inc., a specialty pharmaceutical company focused on pet health, announced today that the Center for Veterinary Medicine of the Food and Drug Administration issued early feedback regarding the potential development path of Promist(TM)-VEL-502 as a treatment for the clinical signs of canine allergy.

Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market (The San Francisco Examiner)
BERKELEY HEIGHTS, N.J., Nov. 16 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA ) announced that it has received a Staff Determination letter from the NASDAQ Stock Market stating that the Company's common stock is subject to delisting from The NASDAQ Global Market because the Company does not comply with the requirement to maintain a minimum $10,000,000 value in stockholders' equity, ...

Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market (PR Newswire via Yahoo! Finance)
Genta Incorporated announced that it has received a Staff Determination letter from the NASDAQ Stock Market stating that the Company's common stock is subject to delisting from The NASDAQ Global Market because the Company does not comply with the requirement to maintain a minimum $10,000,000 value in stockholders' equity, as set forth in Marketplace Rule 4450.